×

Repligen Completes Expansion of U.S. Facility

WALTHAM, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System ("the ATF System"), the most recent addition to the Company's upstream bioprocessing product portfolio. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen's biopharmaceutical customers.

"This expansion satisfies our goal to rapidly transfer ATF System operations, which we acquired from Refine Technology of Pine Brook, NJ in June 2014, to our Waltham facility. This new space is designed to meet the highest standards of quality and service that our customers expect from Repligen, and will improve lead times for product delivery," said Walter C. Herlihy, Ph.D., retiring President and CEO of Repligen.

Tony J. Hunt, COO and named next CEO of Repligen added, "We are immediately addressing customer demand for the current stainless steel ATF System through our new manufacturing facility in Waltham and our expanded technical, service and applications support team, while continuing to execute on the development of a single-use version of the ATF System."

The facility upgrade also expands on areas dedicated to cell culture research and development as well as manufacturing and support of the Company's ELISA test kits and its OPUS® line of pre-packed chromatography columns. An additional 7,500 square feet is reserved for future expansion of the Waltham facility, allowing the Company to remain flexible and responsive to the needs of its biopharmaceutical customers and life sciences partners.

About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media that is used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) System and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of "ready-to-use" chromatography columns under our OPUS® brand that we deliver pre-packed with our customers' choice of purification media. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, constitute forward-looking statements, including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," "anticipate," or "could" and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with risks detailed in Repligen's Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

CONTACT: Sondra S. Newman Director Investor Relations Repligen Corporation (781) 419-1881 snewman@repligen.comSource:Repligen Corporation